A randomized controlled clinical trial using alpha-tocopherol and ascorbic acid in the treatment of moderate traumatic brain injury - Trial PACTR202112742845790

Timeline & Enrollment

Summary

Background: Traumatic brain injury (TBI) is a devastating and complex disease state that accounts for a staggering 40% of all deaths from acute injuries. Currently, TBI is a major public health concern and a leading cause of disability worldwide. Oxidative stress (OS) is a major pathophysiological hallmark of secondary damage in brain injury. Several pharmacological agents, including antioxidants have been tried in the treatment of acute traumatic brain injury with varying degrees of success. Some studies have shown remarkable therapeutic benefits using safe and cheap antioxidants- alpha-tocopherol and ascorbic acid- in the treatment of traumatic brain injury. Such studies are yet to be replicated in our locality. If these agents are found to be effective, they will go a long way in improving the outcome of this devastating disease. Objectives:1. To determine the effects of ascorbic acid, alpha-tocopherol and a combination of both drugs on the mortality of patients with moderate TBI2. To determine the effects of ascorbic acid, alpha-tocopherol and a combination of both drugs on the duration of hospitalization of patients with moderate TBI3. To determine the effects of ascorbic acid, alpha-tocopherol and a combination of both drugs on the Glasgow outcome score of patients with moderate TBI4. To study the demography of moderate TBI in JUTH with respect to age, gender distribution and aetiology

ICD-10 Classifications